{"schema_version":"secwatch.filing_event.v1","accession":"0000947871-26-000310","form_type":"8-K","ticker":"EMBC","cik":"0001872789","company_name":"Embecta Corp.","filed_at":"2026-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.630700+00:00","generated_at":"2026-05-15T09:31:01.558579+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Embecta to acquire Owen Mumford for up to £150M; adds drug-delivery platform","bullets":["Upfront cash payment of £100M at closing; up to £50M earnout based on Aidaptus net sales by end of 2028.","Owen Mumford generated £69.4M revenue in FY2025; transaction expected to close in Embecta's fiscal Q3 2026.","Deal unanimously approved by Embecta board; expected to be accretive to adjusted net income after FY2028.","Acquisition positions Embecta in drug-delivery devices for chronic care (obesity, diabetes, autoimmune, anaphylaxis).","Embecta plans to fund upfront with borrowings under its revolving credit facility."],"urls":{"canonical":"https://secwatch.observer/filing/0000947871-26-000310","json":"https://secwatch.observer/filing/0000947871-26-000310.json","markdown":"https://secwatch.observer/filing/0000947871-26-000310.md","text":"https://secwatch.observer/filing/0000947871-26-000310.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1872789/000094787126000310/0000947871-26-000310-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1872789/000094787126000310/ss6090062_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:31:01.558579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b54283b2bb87652985b8f8e5fd382fd714cf1941","claim":"Embecta Corp. entered into a asset purchase with Owen Mumford Holdings Limited valued at up to £150 million (effective 2026-03-19).","evidence_excerpt":"hat it has entered into a definitive agreement to acquire Owen Mumford Holdings Limited (“Owen Mumford”), a privately held, UK-based innovator and manufacturer of medical devices and drug-delivery technologies, in a transaction valued at up to £150 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1872789/000094787126000310/0000947871-26-000310-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Owen Mumford Holdings Limited"},{"label":"Value","value":"up to £150 million"},{"label":"Effective","value":"2026-03-19"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}